up-front treatment in egfr wild-type patients
Published 9 years ago • 496 plays • Length 16:30Download video MP4
Download video MP3
Similar videos
-
1:02
dr. reckamp on mk-2206 for the treatment of egfr wild-type nsclc
-
5:00
options for up-front therapy in egfr-mutant nsclc
-
1:57
dr. wakelee on benefits of osimertinib in egfr-mutant nsclc treatment
-
8:28
upfront egfr-targeted therapy
-
5:47
egfr tkis for upfront treatment of nsclc
-
20:24
targeted treatment with egfr tkis: front line options
-
10:46
eliminate puppet line with this facial massage and yoga
-
5:06
front-line osimertinib significantly lengthens overall survival in egfr-mutation positive nsclc
-
3:34
repeat biopsy in lung cancer patients with egfr mutation
-
1:23
why are non-mutated egfr genes called "wild type?"
-
3:48
mechanisms of resistance to upfront egfr-targeted therapy
-
3:47
afatinib therapy for uncommon egfr alterations in nsclc
-
3:28
treating beyond progression in egfr-mutant lung cancer
-
23:10
egfr mutation positive tumors: treatment strategies in front line and at relapse
-
4:41
upfront egfr-targeted therapy for nsclc
-
2:02
evolutions in the treatment of egfr-mutated nsclc
-
5:09
egfr therapy as upfront colorectal cancer treatment
-
6:51
osimertinib as frontline therapy in egfr-positive nsclc
-
6:56
first-line therapy in the patient with egfr-mutant lung cancer
-
4:04
treating with osimertinib in egfr-mutated nsclc
-
17:55
front-line targeted therapy for advanced egfr-positive disease
-
41:23
multimodal management of early-stage nsclc: egfr-targeted therapy in perioperative settings